The LDN 2019 Conference

Watch and learn from LDN experts.

The 2019 LDN AIIC Conference had discussions on the following disorders: ALS, Alzheimer's, anxiety, arthritis, autism, autoimmune hepatitis, brain fog, cancer, CFS, complex regional pain syndrome (CPRS), Crohn's, depression, diabetes, dissociative disorder, Epstein Barr virus, fibromyalgia, glioma, Graves’ disease, Hashimoto's, infertility, irritable bowel, leaky brain, leukemia, Lupus, Lyme disease, lymphoma, mast cell activation syndrome (MCAS), melanoma, mental health, mesothelioma, migraines, monoclonal gammopathy of undetermined significance (MGUS), movement disorder, MS, multiple sclerosis, multisystem disorders, myelodysplastic syndromes, obesity, opioid withdrawal, pain, Parkinson's, pituitary dysfunction, premenstrual syndrome (pms), psoriasis, PTSD, recurrent vaginitis, restless leg syndrome (rls), rheumatoid, SMALL intestinal bacterial overgrowth (SIBO), Sjogren's, stress, thyroid, tired brain syndrome, trauma, traumatic brain injury, ulcerative colitis, vulvodynia.

Speakers and Presentations

Click the links below for the videos

 

Biodentical hormones+asthetic+lifestyle - Harpal Bains, MBBS

The role LDN plays in the body's hormonal symphony: how a well-conducted orchestra enhances the efficacy of LDN - Harpal Bains, MBBS

Autoimmune Hepatitis - Paul Battle, PA-C

Client Attraction Secrets - Lesli Bitel, MBA, RDN, LDN

Low Dose Naltrexone for women's health - Phil Boyle, MICGP, MRCGP, MCRN

Intermittent Fasting - Jill Brook, MA

The Use of LDN and Amino Acids in Parkinson's Disease - Ted Cole, DO

The Use of LDN in Parkinson's Disease - Ted Cole, DO

LDN, Endosomes and the Nanophysilogy of Autoimmune Movement Disorders I - Mark Cooper, PhD

LDN, Endosomes and the Nanophysiology of Autoimmune Movement Disorders II - Mark Cooper, PhD

LDN Use in Women's Health I - Olga Cortez, MD

LDN Use in Women's Health II - Olga Cortez, MD

Treatment of Chronic Pain in a Free Clinic Setting - Jill Cottel, MD

The role of LDN in cancer management - Angus Dalgleish, MD

Pharmacology of Low dose Naltrexone in Chronic Pain Management - Samyadev Datta, MD

Mechanism of Action of Low Dose Naltrexone - Stephen Dickson, BSC (hons) MRPharmS

LDN, MS, The LDN Research Trust and Me - Linda Elsegood

Treating Psychiatric Disorders with LDN Case Studies:Trauma-stress disorder, dissociative disorder, anxiety, phobia, pain and hypervigilance - Galyn Forster, MS, LPC 

Latest Th17 Research - Debbie Hamilton, MD

Causes of Hashimoto's - Kent Holtorf, MD

LDN should be considered a first-line therapy for CFS/FM) - Kent Holtorf, M

Safety and Quality in Low-Dose Naltrexone Compounding - James Iversen

LDN and Cellular Hypothyroidism: When TSH is Normal but Reverse T3 is Elevated - Carrie Jones, ND, MPH

LDN and Cellular Hypothyroidism: Why you can't convert T4 into T3 - Carrie Jones, ND, MPH

Patient selection and inflammation - Dana Keaton, ND

The scope of patient selection for LDN - Dana Keaton, ND

Treating chronic pain with low dose naltrexone and ultralow dose naltrexone - Yoon Hang "John" Kim, MD

Getting the most of LDN treatment and Beyond LDN - Yoon Hang "John" Kim, MD

A Pharmacist's Perspective on Comprehensive Immune Health Consultations and Applications of LDN - Amy Lamb, Pharm

Naltrexone Dosing in Traumatic Stress and Dissociative Symptoms - Ulrich Lanius, PhD

Turning down the volume on fibromyalgia pain - Ginevra Liptan, MD

LDN and MDD: A Case Study - Treating Depression in Patients with Autoimmune Conditions - Elizabeth Livengood, NM

Using Low Dose Naltrexone To Help SIBO Patients - Mona Morstein, ND

Making a difference - Michelle Moser, RPh

Sleep - PTSD HPA Axis Dysregulation - LDN & The Gut Brain Barrier - Elissa Mullen, ND

Ocular Uses for Naltrexone - Amber Myers, PharmD

LDN, pain and immunity - Steve Ottersberg, MS

LDN and vulvodynia - Debbie Rice, ND

The Gut-Thyroid Connection, Profound but Under-Appreciated - Michael Ruscio, DC

The Art of LDN Prescribing In Hashimoto’s Thyroiditis - Igor Schwartzman, ND

Infections in Cancer and Autoimmune Disorders II - Armin Schwarzbach, PhD, MD

Infections in Cancer and Autoimmune Disorders I, presented by Markus Berger - Armin Schwarzbach, PhD, MD

Is LDN a magic bullet for Fibromyalgia and Chronic Illness? - Andrew David Shiller, MD

LDN Use in Cognitive Decline, Lyme Disease, and Hashimoto’s Thyroiditis - Pamela Smith, MD

LDN and Multiple Sclerosis - Pamela Smith, MD

LDN for Ophthalmic use - Andy Stein, PharmD

Compounding 101: The Basics of Compounding with Naltrexone - Tara Thompson, PharmD

Immune Dysfunction in Post-Treatment Lyme Disease I - Cory Tichauer, ND

Immune Dysfunction in Post-Treatment Lyme Disease II - Cory Tichauer, ND

Low Dose Naltrexone - Key Ingredient in the Biomedical Treatment of Autism Spectrum Disorder - Brian Udell, MD

Mast cell activation syndrome and potential role for LDN - Leonard Weinstock, MD

Quelling the side effects of immune therapies with LDN - Nasha Winters, ND

Using LDN to Quell the Over-Reactive Autoimmune Conditions Triggered by Many of Today's Cancer Drugs - Nasha Winters, ND

What Patients Need to Know About Telemedicine - Sajad Zalzala, MD

Treatment of Sjogren's Syndrome with LDN - Scott Zashin, MD

"Just try LDN": 3 years of insight from over 1000 patients' use of Low Dose Naltrexone - Sarah Zielsdorf, MD, MS

Graves' Disease - Sarah Zielsdorf, MD, MS

Traumatic Brain Injury: Low Dose Naltrexone and Microglial Modification - Sarah Zielsdorf, MD, MS

 

Question and Answer Sessions

 

     LDN 2019 Conference - Friday Morning Q&A

     LDN 2019 Conference - Friday Afternoon Q&A 

     LDN 2019 Conference - Saturday Morning Q&A

     LDN 2019 Conference - Saturday Afternoon Q&A

     LDN 2019 Conference - Sunday Q&A

Intellectual Property Rights

The intellectual property rights (including without limitation copyright and database rights) to the content in this website are owned by or licensed to the LDN Research Trust unless otherwise indicated.

Website content may be downloaded for personal, non-commercial use only. In all other cases, content originally published on the website may only be reproduced, stored, published or otherwise distributed in any form, with the written prior permission of the LDN Research Trust.